Pre-made Evinacumab benchmark antibody ( Whole mAb, anti-ANGPTL3 therapeutic antibody, Anti-ANG-5/ANGPT5/ANL3/FHBL2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Evinacumab biosimilar, Whole mAb, Anti-ANGPTL3 Antibody: Anti-ANG-5/ANGPT5/ANL3/FHBL2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH).
| Products Name (INN Index) | Pre-Made Evinacumab biosimilar, Whole mAb, Anti-ANGPTL3 Antibody: Anti-ANG-5/ANGPT5/ANL3/FHBL2 therapeutic antibody |
|---|---|
| INN Name | Evinacumab |
| Target | ANGPTL3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Regeneron Pharmaceuticals,Sanofi |
| Conditions Approved | Hyperlipoproteinaemia type II |
| Conditions Active | Hypertriglyceridaemia |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ANGPTL3 |
| Package |
